Atmo Gas Capsule used in Florida State University study assessing gastrointestinal impact of a fasting diet

May 2, 2024. Clinical Research.

Atmo Biosciences’ ingestible gas-sensing capsule was used to assess the impact of an early-time restricted eating diet on gastrointestinal hydrogen production and gastrointestinal transit time.

The Florida State University study entitled “Early time-restricted eating improves markers of cardiometabolic health but has no impact on intestinal nutrient absorption in healthy adults” was published in Cell Reports Medicine. 

The study investigated whether restricting eating to a 6-hr window earlier in the day (8.00 AM -2.00 PM) impacted cardiometabolic health, intestinal energy and macronutrient absorption compared with an energy-matched 12-hour eating schedule (8.00 AM – 8.00 PM).  

The Atmo Gas Capsule was used to measure colonic hydrogen concentrations and gastrointestinal transit times as secondary endpoints. No differences in these endpoints were found between the two groups. 

The main findings of the trial were that restricted eating did not impact intestinal energy or macronutrient absorption compared with ‘regular’ eating, but did improve markers of cardiometabolic health, including insulin sensitivity and 24-hour blood glucose concentrations. 

Atmo Biosciences’ Head of Clinical Affairs Kyle Berean said the trial demonstrated the potential applicability of the Atmo Gas Capsule beyond diagnostic applications. 

“The Atmo Gas Capsule provides insights into gastrointestinal function including key markers such as hydrogen concentration and gastrointestinal transit time. This information is useful not only in diagnosing gastrointestinal disorders, such as dysmotility, but can also be used by researchers to determine the impact and efficacy of dietary interventions.” Dr. Berean said. 

The Atmo Gas Capsule is currently an investigational device exclusively for use in clinical investigations and is not available for sale in the USA.